I wrote an earlier post this week on PML. Today, there is this report:
Biogen revealed another new case of progressive multifocal leukoencephalopathy in a multiple sclerosis patient being treated with Tysabri.
That means that six patients have developed the potentially deadly brain infection since Tysabri (natalizumab), which is partnered with Ireland’s Elan Corp, was reintroduced to the market in July 2006. The case was confirmed late last week.
In the latest case, the patient had been on the drug for 31 months, the longest duration so far. The previous high had been 26 months and the average now is 19 months.